Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Rezolute (RZLT) EPS (Weighted Average and Diluted) (2012 - 2026)

Rezolute recorded quarterly EPS (Weighted Average and Diluted) of -$0.16 in Q1 2026, up 27.27% quarter-over-quarter from -$0.22 in Q4 2025, and up 40.74% year-over-year from -$0.11 in Q1 2025.

Rezolute's EPS (Weighted Average and Diluted) history runs 10 years deep, the most recent figure standing at -$0.16 for Q1 2026.

  • In Q1 2026, EPS (Weighted Average and Diluted) rose 40.74% year-over-year to -$0.16; the TTM figure through Mar 2026 stood at -$0.82 (up 28.7% YoY), while the FY2025 annual figure was -$0.98, up 26.32% from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.16 for Q1 2026 at Rezolute, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.02 in Q2 2022 to a low of -$0.65 in Q1 2022.
  • A 5-year average of -$0.27 and a median of -$0.26 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
  • Across the five-year window, EPS (Weighted Average and Diluted) soared 97.44% in 2022 and plunged 1150.0% in 2023, its largest moves.
  • Rezolute's EPS (Weighted Average and Diluted) stood at -$0.26 in 2022, then decreased by 3.85% to -$0.27 in 2023, then gained by 18.52% to -$0.22 in 2024, then changed by 0.0% to -$0.22 in 2025, then advanced by 27.27% to -$0.16 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.16, -$0.22, and -$0.18 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Rezolute 374.41 Mn 374.41 Mn - -0.16

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.16
Dec 31, 2025 -0.22
Sep 30, 2025 -0.18
Jun 30, 2025 -0.26
Mar 31, 2025 -0.27
Dec 31, 2024 -0.22
Sep 30, 2024 -0.22
Jun 30, 2024 -0.44
Mar 31, 2024 -0.34
Dec 31, 2023 -0.27
Sep 30, 2023 -0.28
Jun 30, 2023 -0.25
Mar 31, 2023 -0.30
Dec 31, 2022 -0.26
Sep 30, 2022 -0.19
Jun 30, 2022 -0.02
Mar 31, 2022 -0.65
Dec 31, 2021 -0.80
Sep 30, 2021 -0.92
Jun 30, 2021 -0.78
Mar 31, 2021 -0.44
Dec 31, 2020 -0.88
Sep 30, 2020 -0.62
Jun 30, 2014 -0.24
Sep 30, 2013 -0.02
Jun 30, 2013 -0.92
Mar 31, 2013 -0.12
Sep 30, 2012 -0.02
Jun 30, 2012 -0.01
Mar 31, 2012 -0.01